Table 1.
Differences in demographic and clinical characteristics among cancer survivors with CIPN by age group (N = 425).
| Characteristic | Age <65 (n=260, 61.0%) (1) |
Age >65 (n=165, 39.0%) (2) |
pa |
|---|---|---|---|
| Mean (SD) | Mean (SD) | ||
| Age, years | 54.52 (8.01) | 70.90 (4.48) | <0.0001 |
| Education, years | 16.07 (3.27) | 16.32 (3.41) | 0.47 |
| Body mass index (kg/m2) | 26.54 (5.61) | 26.49 (5.34) | 0.93 |
| Karnofsky Performance Status score | 80.10 (15.38) | 83.18 (17.43) | 0.06 |
| Number of comorbidities | 1.90 (1.47) | 2.07 (1.91) | 0.31 |
| Self-Administered Comorbidity Questionnaire score | 4.07 (3.41) | 4.24 (3.65) | 0.64 |
| Years since cancer diagnosis | 4.27 (4.61) | 5.72 (5.07) | 0.003 |
| Number of prior cancer treatments | 3.18 (0.98) | 3.02 (0.94) | 0.11 |
| Dose of platinum for patients who received only a platinum (mg/m2) | 704.83 (556.52) | 705.03 (388.64) | 1.00 |
| Dose of taxane for patients who received only a taxane (mg/m2) | 738.28 (290.96) | 805.02 (1090.65) | 0 53 |
| Doses for patients who received both a platinum and a taxane compound | |||
| Platinum dose (mg/m2) | 1715.22 (788.25) | 1882.87 (793.25) | 0.25 |
| Taxane dose (mg/m2) | 818.21 (459.00) | 995.00 (447.69) | 0.04 |
| n (%) | n (%) | ||
| Female | 226 (87.3) | 141 (85.5) | 0.60 |
| Race/ethnicity | 0.001 | ||
| White | 184 (70.8) | 145 (87.9) | 1 < 2 |
| Asian/Pacific Islander | 23 (8.9) | 7 (4.2) | |
| Black | 17 (6.5) | 5 (3.0) | |
| Hispanic/Mixed/Other | 36 (13.9) | 8 (4.9) | 1 > 2 |
| Married/partnered | 154 (61.4) | 98 (60.5) | 0.86 |
| Lives alone | 64 (25.3) | 58 (35.4) | 0.03 |
| Employed | 141 (54.2) | 38 (23.2) | <0.0001 |
| Annual household income | |||
| <$30,000 | 57 (23.4) | 34 (22.7) | |
| $30,000 - $69,999 | 47 (19.3) | 36 (24.0) | 0.44 |
| $70,000 - $99,999 | 38 (15.6) | 26 (17.3) | |
| >$100,000 | 102 (41.8) | 54 (36.0) | |
| Ever smoker | 83 (32.1) | 77 (47.2) | 0.002 |
| Type of cancer | 0.04 | ||
| Breast | 158 (60.8) | 75 (45.5) | 1 > 2 |
| Colon | 22 (8.5) | 21 (12.7) | |
| Lung | 4 (1.5) | 4 (2.4) | |
| Ovarian | 26 (10.0) | 24 (14.6) | |
| Other | 50 (19.2) | 41 (24.9) | |
| Metastatic disease | 149 (58.0) | 103 (63.6) | 0.25 |
| Prior surgery | 238 (91.5) | 156 (95.1) | 0.16 |
| Prior radiation | 156 (60.2) | 94 (57.7) | 0.60 |
| Chemotherapy regimen | |||
| Only a platinum compound | 55 (21.2) | 40 (24.2) | |
| Only a taxane compound | 131 (50.4) | 68 (41.2) | 0.18 |
| Both a platinum and a taxane compound | 74 (28.5) | 57 (34.6) | |
| Patients who had a dose reduction or delay due to neuropathy | 35 (14.0) | 20 (13.0) | 0.77 |
| CIPN in both hands and feet | 184 (70.8) | 105 (63.6) | 0.09 |
| CIPN in only feet | 61 (23.5) | 54 (32.7) | |
| CIPN in only hands | 15 (5.8) | 6 (3.6) | |
Abbreviations: CIPN, chemotherapy-induced peripheral; kg, kilogram; mg, milligram; m2, square meter; neuropathy; SD, standard deviation.
a
P values were calculated using t-tests (continuous variables), Chi-square tests (categorical variables), and Mann-Whitney U test (ordinal household income variable).